<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475566</url>
  </required_header>
  <id_info>
    <org_study_id>06-103</org_study_id>
    <nct_id>NCT00475566</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System</brief_title>
  <acronym>STRIDES</acronym>
  <official_title>A Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-man study is to evaluate the safety and performance of the
      Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with
      atherosclerotic de novo or restenotic native superficial femoral and proximal popliteal
      lesions.

      Abbott Vascular is ceasing data analysis of the STRIDES Clinical Trial after 2 years. The
      decision to discontinue the study is not related to any safety concern. The rationale for
      this proposal is based on the following considerations:

      The performance of DYNALINK-E from STRIDES shows no device- or procedure-related deaths and
      no stent fractures, and the rate of additional revascularizations has been stable since
      approximately 14 months after the procedure.

      Evaluations of the bare metal nitinol DYNALINK and ABSOLUTE stents in the clinical literature
      show low rates of death, reintervention and stent fracture, which are consistent with STRIDES
      and demonstrate the safety of the nitinol stent platform of the DYNALINK-E.

      Long-term animal studies show no concerns with the drug or polymer coating of DYNALINK-E -
      everolimus tissue concentration drops below the quantifiable limit by approximately 17 months
      after implant, and vascular response to the coating is normal with widely patent lumens and
      struts incorporated into vessel tissue.

      The safety and performance of the DYNALINK-E has been substantiated by its clinical and
      pre-clinical data, and by the clinical data of similar products. Given the demonstrated
      mechanical integrity of the stent along with the evidence of a healthy long-term vascular
      response, there is a reasonable expectation of continued low event rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, Non-Randomized, Single-arm, Multi-center, Clinical Study to Evaluate the
      Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for the
      Treatment of Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal
      Popliteal Artery Lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent binary restenosis (&gt;50% stenosis), as measured by duplex ultrasound</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic in-stent binary restenosis rate (&gt;50%)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic mean in-stent late loss, in-stent mean minimum lumen diameter (MLD), percent diameter stenosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary, and secondary patency</measure>
    <time_frame>1, 6, 12, 18 months, 2, 3, 4, 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynalink®-E everolimus-eluting peripheral stent</intervention_name>
    <description>Stenting of atherosclerotic de novo or restenotic lesions (&gt; 50% stenosis) in the native superficial femoral or proximal popliteal artery</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynalink®-E, everolimus-eluting peripheral stent</intervention_name>
    <description>Stenting of atherosclerotic de novo or restenotic lesions (&gt; 50% stenosis) in the native superficial femoral or proximal popliteal artery</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rutherford Becker Category 2-5

          -  Single de novo or restenotic lesion in the superficial femoral or proximal popliteal
             artery

          -  Disease segment length 30-170 mm

          -  &gt;50% diameter stenosis or total occlusion

          -  Target reference vessel diameter 4.3-7.3 mm

        Exclusion Criteria:

          -  Target lesion previously treated with stent or surgery

          -  Rutherford Becker Category 0, 1, or 6

          -  Immunosuppressive disorder or currently receiving immunosuppressive agents

          -  Serum creatinine &gt;2.5 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Lammer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allgemeines Krankenhaus der Stadt Wien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien- AKH Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Blasius Hospital</name>
      <address>
        <city>Dendermonde</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL St. Jan</name>
      <address>
        <city>Gent</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jewish Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura di Montevergine</name>
      <address>
        <city>Mercogliano</city>
        <zip>83013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marie-Helene Bettiol</name_title>
    <organization>Abbott Vascular</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

